Share

    


Home / Search Results

Search Results

You searched for:

If you are looking for legislative action, look no further than your state's legislatures. Most—if not all—states have had issues relating to oncology care and healthcare in general come up during their 2023 sessions.
At the end of last month, the Centers for Medicare & Medicaid Services (CMS) released the much-anticipated calendar year (CY) 2020 Medicare Payment rules. Touted by CMS as an effort to “empower patients with price transparency and increase competition to lower costs for Medicare beneficiaries,” the proposed Outpatient Prospective Payment System (OPPS) rule for 2020 introduces new price transparency …
On July 25, 2018, the Centers for Medicare & Medicaid Services (CMS) released the CY 2019 Outpatient Prospective Payment System (OPPS) proposed rule, and we are seeing several efforts to continue the push towards “site neutral” payments in off-campus provider-based departments (PBDs). This rule was issued weeks after the CY 2019 Physician Fee Schedule (PFS) proposed rule, and the atypical lag time …
issues Another Wild Ride? BY LEAH RALPH Congress rang in the New Year with a massive tax overhaul and a government shutdown over immigration—another unpredictable year in Washington, D.C., seems like a foregone conclusion. Now several months into 2018, is the turbulence slowing down or ratcheting up? Although MedPAC’s January vote recom- mended that Congress eliminate the Merit-Based Incentive …
In August 2015 the Health Resources and Services Administration (HRSA) released its much-anticipated “mega-guidance” on the 340B Drug Pricing Program, proposing new limits on the program but stopping short of a complete overhaul, prompting mixed reviews from stakeholders.
Summer headlines have been dominated by congressional efforts to repeal and replace portions of the Affordable Care Act (ACA) and find a politically palatable path forward to shoring up the nongroup insurance market.
Drug pricing reform is in the news again this week as the Medicare Payment Advisory Commission (MedPAC) voted unanimously April 6 in support of the Commission’s multi-part Part B recommendations that include a Drug Value Program (DVP) with elements that align with President Trump’s interest in requiring drug companies to bid for government business. “Despite Trump’s outreach to industry leaders and …
In early March, the Centers for Medicare and Medicaid Services (CMS) issued a proposal to implement a national demonstration program that would fundamentally change the way Medicare pays physicians and hospitals for Part B drugs.